In summary, leptin has been confirmed as the target of PF in ameliorating the symptoms in PI-IBS rats, such as excessive fibrotic remodeling in the submucosa and depression- and anxiety-like behaviors via the inhibited activation of the leptin/LepRb downstream pathway—the PI3K/AKT pathway. Here, AKT1 is linked to irritable bowel syndrome.